Bloomington, Minnesota Clinical Trials

A listing of Bloomington, Minnesota clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 801 clinical trials
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine - the REBUILD-2 Study (REBUILD-2)

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days …

Minneapolis Clinic of Neurology
 (5.6 away) Contact site
  • 0 views
  • 20 Oct, 2022
  • +79 other locations
Lead EvaluAtion for Defibrillation and Reliability (LEADR)

The study is designed to assess the safety and efficacy of the Next Generation ICD lead.

Minneapolis Heart Institute Foundation
 (7.2 away) Contact site
  • 7 views
  • 23 Oct, 2022
  • +46 other locations
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (DELIVER-MS)

The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide overall treatment …

University of Minnesota
 (9.7 away) Contact site
  • 238 views
  • 04 Oct, 2022
  • +22 other locations
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)

This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination with PAC in patients with platinum resistant recurrent ovarian cancer.

Metro Minnesota Community Oncology Research Consortium
 (7.7 away) Contact site
  • 31 views
  • 04 Oct, 2022
  • +126 other locations
Eliminating Monitor Overuse Trial (EMO Trial)

The purpose of this study is to identify the optimal deimplementation strategies for an overused practice: continuous pulse oximetry monitoring of children hospitalized with bronchiolitis who are not receiving supplemental oxygen.

Children's Minnesota
 (8.4 away) Contact site
  • 0 views
  • 04 Oct, 2022
  • +50 other locations
ACTIV-6: COVID-19 Study of Repurposed Medications

The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19. Participants will receive either study drug or placebo. They will self-report any new or worsening symptoms or medical events they may experience while taking …

University of Minnesota
 (9.7 away) Contact site
  • 357 views
  • 04 Oct, 2022
  • +92 other locations
A Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) (VICTORION-2P)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).

Novartis Investigative Site
 (5.4 away) Contact site
  • 1 views
  • 10 Oct, 2022
  • +661 other locations
A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

An investigation of the efficacy and safety of up to 70 weeks of treatment with Tildacerfont in subjects with classic CAH who have elevated biomarkers at baseline on their current GC regimen. Optional open label treatment extension period up to 240 weeks with 200mg tildacerfont QD.

17-hydroxyprogesterone
21-ohd
prednisolone
deficiency
prednisone
Spruce Clinical Site
 (9.7 away) Contact site
  • 28 views
  • 07 Oct, 2022
  • +56 other locations
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 28 weeks in approximately 81 pediatric patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The study consists of a 28-week double blind, placebo-controlled period, followed by 24 weeks …

deficiency
21-ohd
classic congenital adrenal hyperplasia
Neurocrine Clinical Site
 (9.2 away) Contact site
  • 3 views
  • 07 Oct, 2022
  • +38 other locations
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

An investigation of the ability of Tildacerfont to reduce supraphysiologic glucocorticoid dosing in classic CAH subjects up to 76 weeks of treatment. Optional open label extension up to 240 weeks.

deficiency
prednisone
21-ohd
prednisolone
Spruce Study Site
 (9.7 away) Contact site
  • 10 views
  • 07 Oct, 2022
  • +54 other locations